SMARCB1 and cancer: On the other hand, in cancer cells lacking SMARCA4, SMARCB1, ARID1A, and PBRM1 of the SWI/SNF chromatin remodeling complex, inhibition of EZH2 (subunits of Zeste 2 Polycomb Repressive Complex 2; such as tazemetostat1 or valemetostat) can cause synthetic lethality (19).